elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Urothelial cancer
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Urothelial cancer
RIS
0.000
(Research Intensity Score)
Papers
52
Top papers
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2025 · 76 citations
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
2025 · 89 citations
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
2023 · 185 citations
Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
2025 · 41 citations
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer
2024 · 57 citations
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study
2025 · 26 citations
The evolving treatment landscape of metastatic urothelial cancer
2024 · 38 citations
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
2019 · 492 citations
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 · 1344 citations
Newest papers
Rapid Systemic Progression After Ureteroscopic Holmium: YAG Laser Ablation for High‐Grade Upper Tract Urothelial Carcinoma in a Solitary Kidney: A Case Report
2026 · 1 citations
Integrative Genomic Analysis Reveals Molecular and Clinical Disparities between Bladder and Upper Tract Urothelial Carcinoma in K-MASTER Program
2026
Platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma: a real-world study
2026
Editorial Comment on Rapid Systemic Progression After Ureteroscopic Holmium: YAG Laser Ablation for High‐Grade Upper Tract Urothelial Carcinoma in a Solitary Kidney: A Case Report
2026
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma
2026
First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study
2026 · 1 citations
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab
2026 · 1 citations
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2025 · 76 citations
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
2025 · 89 citations
Browse all papers →
Urothelial cancer's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Urothelial cancer's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link